Celgene Corp - Company Profile
Powered by
All the data and insights you need on Celgene Corp in one report.
- Save hours of research time and resources with
our up-to-date Celgene Corp Strategy Report
- Understand Celgene Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celgene Corp (Celgene), a subsidiary of Bristol-Myers Squibb Co, is an integrated biopharmaceutical company that discovers, develops, manufactures, and markets novel gene and protein regulation therapies for the treatment of cancer and immune-inflammatory diseases. Its major product portfolio includes Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; and Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers, among others. The company sells its products through own sales organizations and distributors in Europe, the Middle-East, the Americas, and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.
Celgene Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed | Vidaza |
Paclitaxel Protein-Bound Particles For Injectable Suspension (Albumin-Bound) | Abraxane |
Thalidomide | Istodax |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
Competitor Comparison
Key Parameters | Celgene Corp | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
City | Summit | New Brunswick | Kenilworth | Paris | Basel |
State/Province | New Jersey | New Jersey | New Jersey | Ile-de-France | - |
No. of Employees | - | 131,900 | 72,000 | 87,994 | 76,057 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward